News for Rigel Pharmaceuticals, Inc. (RIGL)

PR NewswireSOUTH SAN FRANCISCO, Calif., April 4, 2025 SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nas

PR NewswireSOUTH SAN FRANCISCO, Calif., March 10, 2025 SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIG

The three major indices were mostly flat in midday trading Wednesday with the S&P 500 and Nasdaq slightly under the flatline and the Dow Jones up 39 points.

Total Revenue for 2024: $145 million, a 39% increase over 2023.Net Product Sales for Q4 2024: $46.5 million, a 58% growth year over year.TAVALISSE Net Product

Mar 04, 2025 / 09:30PM GMTOperator Greetings, and welcome to Rigel Pharmaceuticals financial conference call for the fourth quarter and full year 2024. (Operato

Rigel (RIGL) delivered earnings and revenue surprises of 45.45% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireSOUTH SAN FRANCISCO, Calif., March 4, 2025 Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net prod

Quarterly Revenue: Achieved $57.6 million, surpassing the estimated $51.73 million.Quarterly EPS: Reported at $0.81, significantly exceeding the estimated $0.4

Rigel Pharmaceuticals Inc (RIGL) is set to release its Q4 2024 earnings on March 4, 2025. The consensus estimate for Q4 2024 revenue is $51.73 million, and the

PR NewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)

Transaction Overview On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) made a strategic decision to reduce its stake in Rigel Pharmaceuticals Inc

In a recent transaction dated December 31, 2024, Invesco Ltd. (Trades, Portfolio) significantly reduced its position in Rigel Pharmaceuticals Inc. by 99.39%, se

Rigel Pharmaceuticals projects positive financial growth, with revenue expected to reach $200-210M by 2025 and positive net income.

Rigel Pharmaceuticals, Inc. (RIGL) said it expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 million for the same period of 2023.

PR NewswireSOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL),

PR NewswireSOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasda

Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib. Read why RIGL stock is no longer a Strong Buy.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 200 points on Tuesday. The Dow traded up 0.53% to 43,132.84 whi...

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced tod…